Implantation of the Ventura interatrial shunt, while safe, does not improve clinical outcomes or prognosis in patients with HF and preserved LVEF.

For Sources of Funding and Disclosures, see page 3. Power DA, Lampert J, Camaj A, Bienstock SW, Kocovic N, Bayes‐Genis A, Miller MA, Bayés‐de‐Luna A, Fuster V. Cardiovascular complications of ...

Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced today the ...

The Adona implant represents the next-generation of shunt technology, designed for dynamic interatrial flow that can be modified based on patient-specific hemodynamic needs," said Dr. Singh ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Consultant ...

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

TCT 468: No-Implant Interatrial Shunt for Heart Failure With Preserved and Mildly-Reduced Ejection Fraction: Twelve-Month Outcomes From Multi-Center Pilot Feasibility Studies Receive the the latest ...

Despite this, the company maintains a positive outlook on the acquisition, viewing V-Wave’s Ventura Interatrial Shunt device as vital for treating heart failure. Nevertheless, investors are ...

DiveWire guarantees visibility for your news announcements through instant distribution to MedTech Dive’s audience and its 56,000 newsletter subscribers for 21 days.

a left-to-right interatrial shunt; trace-to-mild aortic insufficiency; a well-seated mitral valve prosthesis with no regurgitation and a mean transmitral gradient of 5 mm Hg; and a right ...